Profile of secukinumab in the treatment of psoriasis: current perspectives
about
Secukinumab - First in Class Interleukin-17A Inhibitor for the Treatment of Psoriasis.Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.
P2860
Profile of secukinumab in the treatment of psoriasis: current perspectives
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Profile of secukinumab in the treatment of psoriasis: current perspectives
@ast
Profile of secukinumab in the treatment of psoriasis: current perspectives
@en
Profile of secukinumab in the treatment of psoriasis: current perspectives
@nl
type
label
Profile of secukinumab in the treatment of psoriasis: current perspectives
@ast
Profile of secukinumab in the treatment of psoriasis: current perspectives
@en
Profile of secukinumab in the treatment of psoriasis: current perspectives
@nl
prefLabel
Profile of secukinumab in the treatment of psoriasis: current perspectives
@ast
Profile of secukinumab in the treatment of psoriasis: current perspectives
@en
Profile of secukinumab in the treatment of psoriasis: current perspectives
@nl
P2093
P2860
P356
P1476
Profile of secukinumab in the treatment of psoriasis: current perspectives
@en
P2093
Melvin W Chiu
Michael Roman
Vandana K Madkan
P2860
P304
P356
10.2147/TCRM.S79053
P407
P577
2015-01-01T00:00:00Z